Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What is the current market size of the tumor profiling industry, and what growth rate is it expected to achieve?
The tumor profiling market size has grown rapidly in recent years. It will grow from $10.16 billion in 2024 to $11.21 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to increasing prevalence of cancer cases, rising demand for personalized medicine, growing healthcare expenditure, rising adoption of companion diagnostics, and increasing awareness about early cancer detection.
The tumor profiling market size is expected to see rapid growth in the next few years. It will grow to $16.48 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to rising adoption of liquid biopsy techniques, increasing investment in cancer research and development, growing aging population, growing implementation of targeted therapies, and increasing number of cancer research collaborations. Major trends in the forecast period include a shift towards companion diagnostics, a rise in multi-gene testing, technological advancements in next-generation sequencing, integration of artificial intelligence (AI) in cancer diagnostics, and advancements in tumor profiling technologies.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24420&type=smp
What are the major drivers contributing to the growth of the tumor profiling market?
The rise in demand for personalized medicine is expected to drive the growth of the tumor profiling market going forward. Personalized medicine refers to an approach that tailors healthcare treatments to the individual characteristics of each patient. This increase is driven by patients seeking more precise therapies that offer better outcomes and fewer side effects compared to traditional treatments. The tumor profiling is helping personalized medicine by identifying specific genetic mutations and biomarkers in a patient’s tumor, enabling targeted treatments and reducing side effects. For instance, in February 2024, according to a report published by the Personalized Medicine Coalition, a US-based organization dedicated to advancing personalized medicine, personalized medicines accounted for more than one-third of all new drug approvals in 2023, marking the fourth consecutive year of this trend. Therefore, the growing demand for personalized medicine is driving growth in the tumor profiling market.
What are the major market segments driving the growth of the tumor profiling industry?
The tumor profiling market covered in this report is segmented –
1) By Technique: Genomics, Proteomics, Epigenetics, Metabolomics
2) By Technology: Sequencing Techniques, Quantitative Polymerase Chain Reaction (qPCR), Immunohistochemistry, In Situ Hybridization (ISH), Microarray
3) By Application: Personalized Cancer Medicine, Oncological Diagnostics, Research
Subsegments:
1) By Genomics: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Microarrays, Sanger sequencing
2) By Proteomics: Mass Spectrometry (MS), Protein Microarrays, Immunohistochemistry (IHC), Western Blotting
3) By Epigenetics: DNA Methylation Analysis, Chromatin Immunoprecipitation Sequencing (ChIP-seq), Histone Modification Profiling, Non-Coding RNA Analysis
4) By Metabolomics: Nuclear Magnetic Resonance (NMR) Spectroscopy, Gas Chromatography-Mass Spectrometry (GC-MS), Liquid Chromatography-Mass Spectrometry (LC-MS), Capillary Electrophoresis-Mass Spectrometry (CE-MS)
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/tumor-profiling-global-market-report
What evolving trends are creating new opportunities in the tumor profiling market?
Major companies operating in the tumor profiling market are focusing on developing advanced solutions, such as artificial intelligence (AI)-powered diagnostic solutions, to enhance accuracy and efficiency in cancer treatment. Artificial intelligence (AI) refers to the use of advanced computational methods to analyze complex genomic, proteomic, and clinical data, enabling faster diagnoses, personalized treatment strategies, and better monitoring of disease progression. For instance, in January 2025, Panakeia Technologies LTD, a UK-based company specializing in AI-driven software for cancer diagnosis and treatment, launched PANProfiler Colon, an AI-driven software solution specifically designed to profile key molecular biomarkers such as microsatellite instability (MSI) and mismatch repair deficiency (dMMR)—from H and E-stained images of colon cancer tissue samples. This digital tool enables rapid and accurate molecular profiling of tumors, which is essential for diagnosing colorectal cancer, identifying cases of Lynch syndrome, and informing personalized treatment decisions.
Who are the key market players contributing to the growth of the tumor profiling industry?
Major companies operating in the tumor profiling market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Hologic Inc., Illumina Inc., Sysmex Corporation, QIAGEN N.V., Exact Sciences Corporation, Guardant Health Inc., GenScript Biotech Corporation, NeoGenomics Inc., Caris Life Sciences Inc., Tempus Inc., Foundation Medicine Inc., NanoString Technologies Inc., Personalis Inc., Boreal Genomics Inc., Strand Life Sciences Pvt. Ltd., HTG Molecular Diagnostics Inc., Lucence Health Inc., Predictive Oncology Inc.
Which regions are leading the growth of the tumor profiling market globally?
North America was the largest region in the tumor profiling market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tumor profiling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Tumor Profiling Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/customise?id=24420&type=smp
Need Customized Data On Tumor Profiling Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24420&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
